Merck & Co., Inc. (MRK)
Wall Street Analysts See Merck (MRK) as a Buy: Should You Invest?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Is Merck Stock a Buy?
It's been a rough start to 2025 for Merck (MRK 2.08%) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates with 7% revenue growth and earnings per share (EPS) of $1.72 for the quarter ended Dec. 31, weak sales in China and soft forward guidance were seen as a disappointment.
Why Merck (MRK) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
I'm Buying Discounted Dividend Icons Up To 6% Yield
Great dividend stocks should offer a mix of durability, solid income generation, and growth prospects. In this article, I highlight 2 such names, both of which are trading at discounted valuations compared to historical norms. Both offer high yields and carry strong balance sheets, making them dividend juggernauts worth considering for potentially strong total returns.
Exclusive: Merck vaccine case linked to HHS Secretary Kennedy delayed, company says
Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus vaccine in a case with ties to U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr, the company said.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
3 Blue-Chip Dividend Stocks Trading at Multiyear Lows
Buying a dividend stock at a cheap valuation can be a great move for several reasons. If a stock has declined in price but management has maintained its payout, new buyers can get a higher-than-usual yield from the investment.
US pharma giant Merck backs healthcare marketplace HD in Southeast Asia
Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare industry. Just last month, AWS and General Catalyst announced their partnership to speed up the development and deployment of healthcare AI tools.
Jim Cramer Says These 2 Large Cap Dividend Stocks Are Hot February Buys
Media personality Jim Cramer often makes bold statements about companies and a lot of times, he proves himself correct.
Merck: 4 No-Brainer Reasons to Buy This Dip
Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the market can be unforgiving when companies even slightly miss expectations or forecasts.
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What's Next?
Merck & Co . (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name drugs such as Keytruda, and the myriad of commercials the company shows on popular television channels we're all exposed to.
Merck: Don't Fight The Tape, How Low Can It Go?
Despite Merck & Co., Inc.'s strong fundamentals and promising pipeline, current negative sentiment suggests avoiding the stock until it stabilizes and shows signs of recovery. Merck's stock is undervalued but could face further declines, with potential prices dropping to $80, $70, or even $60. The stock market's irrationality can outlast your solvency; avoid the pain of catching a falling knife by waiting for a confirmed bottom in MRK stock.
